

January 2011

**ANNUAL DECLARATION OF INTERESTS
GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE
BOARD OF DIRECTORS
1 January – 31 December 2010**

GOLD participants disclose relationships (personal benefits, shares, and non-personal interests) with profit-making organizations each year using the following definitions.

- 1. *Personal Benefits*** refers to fees for lectures, advisory committees or consultancy services either intermittent or regular, from which a GOLD member benefits personally. This includes ongoing attendance at advisory board meetings.
- 2. *Shares*** refers to any shares in the pharmaceutical industry, excluding unit trusts, pension plans or mutual funds, and it refers to shares held by a GOLD member or family members (spouse/dependent children <18 yrs). The company is to be listed, not the number of shares.
- 3. *Non-Personal Interests*** refers to fees or grants paid to a GOLD Committee member (or the Department/Institution on behalf of a GOLD member) and used for research, education, equipment, salaries, etc.

For each category, items are included in one of two categories: payment or service is valued in excess of \$10,000 (US) but less than \$10,000 and payment or service is valued in excess of \$10,000. The information disclosed by each member of the Board of Directors for the year 2010 is presented in an effort to be as transparent as possible. For more complete background about this process, see “Annual Declaration of Interests: Global Initiative for Chronic Obstructive Lung Disease (GOLD)” on the website at: <<http://www.goldcopd.org>>.

SUMMARY FOR YEAR 2010:

Antonio Anzueto, San Antonio, Texas, US: *Personal Benefits* <\$10,000: Dey, Forest Labs, Sepracor. *Personal Benefits* >\$10,000: AstraZeneca, Bayer-Shering Pharma, Boehringer-Ingelheim, GlaxoSmithKline, Pfizer. *Shares:* none. *Non-Personal Interests* >\$10,000: GlaxoSmithKline, Lilly, Pfizer.

Jean Bourbeau, Montreal, Quebec, Canada: *Personal Benefits* <\$10,000: AstraZeneca, Boehringer-Ingelheim, Novartis, Nycomed, Pfizer. *Personal Benefits* >\$10,000: GlaxoSmithKline. *Shares:* none. *Non-Personal Interests* > \$10,000: AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Novartis, Nycomed, Merck, Pfizer.

Teresita DeGuia, Quezon City Philippines: *Personal Benefits* <\$10,000: AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Novartis, Nycomed, Pfizer, United Lab (Philippines). *Personal Benefits* >\$10,000: Schering-Plough. *Shares:* none. *Non-Personal Interests:* none

David Hui, HongKong PRC: *Personal Benefits* <\$10,000: AstraZeneca, Daiichi-Sanchio. *Shares:* none. *Non-Personal Interests* >\$10,000: Boehringer-Ingelheim, GlaxoSmithKline.

Fernando Martinez, Ann Arbor, Michigan: *Personal Benefits* <\$10,000: Almirall, AstraZeneca/MedImmune, Bayer, Boehringer Ingelheim, France Foundation, Forest, HCRC,

MedEd, Merck Sharp & Dohme, Pearl, Pfizer, Prescott. *Personal Benefits* >\$10,000: GlaxoSmithKline, Novartis, Nycomed/Forest. *Shares*: none. *Non-Personal Interests* <\$10,000: Actelion, Gilead, Johnson/Johanson. *Non-Personal Interests* >\$10,000: GlaxoSmithKline, Nycomed.

Michiaki Mishima, Kyoto, Japan: *Personal Benefits* <\$10,000: AstraZeneca, Kyorin, Novartis, Otsuka, Schering-Plough, Teijin. *Personal Benefits* >\$10,000: Boehringer-Ingelheim, GlaxoSmithKline. *Shares*: none. *Non-Personal Interests* >\$10,000: Astellas, AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Kyorin, Novartis, Otsuka, Schering-Plough, Teijin.

Damilya Nugmanova: *Personal Benefits* <\$10,000: AstraZeneca, Berlin Chemi Menarini, Boehringer-Ingelheim, GlaxoSmithKline, Novartis, TEVA. *Shares*: none. *Non-Personal Interests* <\$10,000: Boehringer-Ingelheim, GlaxoSmithKline, Novartis.

Alejandra Ramirez, Mexico City, Mexico: *Personal Benefits* <\$10,000: Boehringer-Ingelheim, Novartis. *Shares*: none. *Non-Personal Interests*: none.

Roberto Rodriguez-Roisin, Barcelona Spain: *Personal Benefits* <\$10,000: Boehringer-Ingelheim/Pfizer, Chiesi, GlaxoSmithKline, Kyorin, Merck Sharp & Dohme, Novartis, Nycomed, Procter & Gamble, UCB. *Shares*: none. *Non-Personal Interests* <\$10,000: Almirall, Esteve, SA.

Robert A. Stockley, Birmingham, UK: *Personal Benefits* <\$10,000: AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Nycomed, Talecris Biotherapeutics. *Shares*: none. *Non-Personal Interests* >\$10,000: AstraZeneca, Talecris Biotherapeutics.

Jorgen Vestbo, Hvidore Denmark: *Personal Benefits* <\$10,000: AstraZeneca, Boehringer-Ingelheim, Chiesi, Nycomed, Pfizer. *Personal Benefits* >\$10,000: GlaxoSmithKline. *Shares*: none. *Non-Personal Interests* >\$10,000: GlaxoSmithKline.

Jadwiga A. Wedzicha, London, UK: *Personal Benefits* <\$10,000: Boehringer-Ingelheim/Pfizer, Chiesi, Novartis, Nycomed. *Personal Benefits* >\$10,000: GlaxoSmithKline. *Shares*: none. *Non-Personal Interests* >\$10,000: AstraZeneca, Chiesi, GlaxoSmithKline, Novartis.

All members confirmed no relation to, or income from, the tobacco industry.